CymaBay stock: buy or sell?

CBAY stock price: $6.68 -2.62% At close on June 26th, 2019

Updated on:
June 26th, 2019


CymaBay shares eased -2.62% to $6.68 today. On June/18 CBAY skyrocketed an exceptional 7.61%.

Cymabay Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases.

Should I buy CymaBay stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Following a trading plan helps to make decisions easier, quicker and with less hesitations. At, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

None of our preferred buy setups matches with CymaBay stock situation right now, therefore this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is CymaBay Therapeutics stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. At, we gathered 8 ratings published for CBAY stock in the last 30 days.

The general sentiment of these ratings is bullish for CBAY stock, with 6 positive ratings.
Is CBAY a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-6-17B. Rileyn/aHold
2019-6-12HC Wainwrightn/aBuy
2019-6-11Piper Jaffray CompaniesOverweightMarket Perform
2019-4-23Raymond Jamesn/aBuy
2019-2-22Leerink Swannn/aOutperform
2019-2-1Cantor Fitzgeraldn/aBuy

CymaBay stock analysis

Daily outlook

CymaBay Therapeutics eased a terrible -2.62% and closed at $6.68.

Shares of CymaBay ended today at $6.68 and eased a terrible -2.62%. Since price and SMA200d lines crossed down on June 11th, CBAY fell $-4.41 per share (-39.77%). Since SMA100d and SMA200d crossed up on May, CBAY price slid a -48.14%.

CBAY stock chart (daily)

Weekly outlook

After boosting an amazing 11.17% in a week last week, CymaBay Therapeutics closed this week at $6.68 and plummed a frightening -5.52%.

Since price and 40-weeks moving average lines crossed down by mid June, CBAY fell $-4.83 per share (-41.96%). Stocks under the 40w moving average line are usually not recommended for average traders. Since early May when SMA20w and SMA40w crossed up, CBAY price slipped $-6.44 per share (-49.09%).

CBAY stock chart (weekly)

CymaBay stock price history

CymaBay stock went public on February 3rd, 2014 with a price of $5.001. Since then, CBAY stock grew a 33.60%, with an average of 6.70% per year. If you had invested right after CBAY's IPO a $1,000 in CymaBay stock in 2014, it would worth $336.00 today.

1: Adjusted price after possible price splits or reverse-splits.

CymaBay stock historical price chart

CBAY stock reached 52-week highs on July at $14.94, and all-time highs 2018-03-05 with a price of 15.59.

CymaBay stock price target is $14.00

Nobody can reliably foresee how stock prices may evolve in the future. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' CBAY stock price predictions in the hope that they will be met as they may be wrong and not met. We have 7 price targets for CymaBay Therapeutics stock posted in the last month:
CBAY stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-6-17B. RileySet Price Targetn/a$7.00-
2019-6-13CitigroupLowers Target$21.00$12.00-42.9%
2019-6-12HC WainwrightReiterates$24.00$12.00-50%
2019-6-11Piper Jaffray CompaniesLowers Target$30.00$8.00-73.3%
2019-4-23Raymond JamesSet Price Targetn/a$18.00-
2019-2-1Cantor FitzgeraldReiteratesn/a$20.00-
(in average)$25.00$14.00-44.0%
The price target for CymaBay Therapeutics stock is $14.00, moving in a range between $21.00 and $7.00. In average, analysts' outlook on CBAY price target is negative, reducing the target by a -44.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On February, CymaBay failed to meet the expectations of the analysts and posted a fatal EPS of $-0.32 per share when experts were expecting $-0.36.
CBAY earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to , last anual sales report draw of to $10.00 M dollars. , its profit margin (compared to revenues) to -275.57%, that is $-27.56 million.

CBAY annual Sales and Income evolution
2017$10 M-$-27.56 M-275.6%-

Quarterly financial results

Reported quarter earnings marked $-19.45 M with a profit margin of . Profit margin remained stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing revenues to same quarter last year, CymaBay sales marked a spooky correction and plummed a -100.00%. Looking back to recent quarterly results, CymaBay posted 4 negative quarters in a row.
CBAY quarterly Sales and Income evolution
2017-Q1$4.79 M-$-5.35 M-111.7%-
2017-Q4$5.21 M8.71%$-5.04 M-96.9%-5.74%

CymaBay ownership

When you are planning to buy a company, it's worth to have a look its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For CymaBay Therapeutics, 0.74% of all outstanding shares are owned by its staff.

Bearish positions for CBAY stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to CymaBay:

Market cap$458.9 M$73.7 B$242.9 B$2.4 B$2.2 B
Total shares68.7 M1,640.0 M5,550.0 M58.4 M56.4 M
Float shares53.9 M1,630.0 M5,520.0 M56.8 M45.7 M
  - Institutional holdings (%)88.5%75.0%76.2%85.6%85.8%
  - Insider holdings (%)0.7%0.1%0.0%2.7%13.4%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

CymaBay summary

Wednesday, June 26th, 2019
Day range$6.62 - $7.01
Previous close$6.86
Session gain-2.62%
Average true range$1.09
50d mov avg$11.09
100d mov avg$11.51
200d mov avg$10.64
Daily patternlt03a
Weekly pattern

CymaBay performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We compared CymaBay Therapeutics against Bristol-Myers Squibb, Pfizer, PTC Therapeutics and Xencor in the following table:
CBAYCymaBay Therapeut...-49.70%-14.58%-50.22%
BMYBristol-Myers Squ...-5.01%-10.34%-16.33%
PTCTPTC Therapeutics9.88%29.21%22.62%

CymaBay competitors

One check before trading any stock is to review a list of its competitors, in this case for CymaBay Therapeutics. We chose 4 companies as CymaBay Therapeutics competitors as they are in the same industry or have similar market objectives.